Scripps Laboratories is a bulk manufacturer of high quality proteins and immunoreagents for the diagnostic industry and research community. Our expertise, experience, and commitment to producing the best product available have led us to become one of the world’s premier providers of proteins and immunoreagents.

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., is a commercial stage biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases.

A private equity firm that aims to provide investors with a predictable high yield by building relationships with stable, profitable businesses.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more.

BioFluidica® is a biotechnology company dedicated to eliminating obstacles to the adoption of liquid biopsy as a tool for researchers and clinicians. Our strategy combines cutting-edge microfluidics, advanced immunoaffinity chemistries, automation hardware, and workflow optimizations to improve sensitivity and specificity, increase throughput, and enable the isolation and enrichment of multiple disease biomarkers from a single sample.

When protein –based biotherapeutics first came to the market the importance of purity was the highest outmost objective and the cost was not the major factor. We are living in the age of biosimilars where the purity is given but the cost of production is critical to succeed. Sterogene’s focus is to provide chromatography resins and other products that can result in significant savings to our customers. Our resins are extremely stable, NaOH cleanable and provide long cycle life. We have resins that are validated for over 100 cycles and used in the production of licensed pharmaceuticals. Our Direct Capture technology saves significant cost for our customer due to elimination of costly filtration steps and overall resulting in higher purity and lower production time. Our mission is to provide our customers with innovative products of the highest quality, enabling them to efficiently develop and manufacture safe and efficacious products. We can achieve this by developing custom purification products that meet the regulatory requirements of governing bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), while allowing significant cost-saving for our customers.

Embark on a journey with NeoGenesis, where our roots are deeply intertwined with the fascinating realm of stem cell science. Founded by the visionary research scientist, Dr. Greg Maguire, our legacy spans more than three decades, marked by a relentless pursuit of excellence in stem cell research. Dr. Maguire's leadership laid the groundwork for our revolutionary S2RM® technology, a testament to our commitment to advancing the field of stem cell-based therapeutics and cosmeceuticals. Throughout our evolution, a team of seasoned scientists has propelled us forward, dedicated to pioneering innovations that positively impact lives worldwide. Our collaborations with leading research facilities have cultivated an environment of shared knowledge, fostering breakthroughs in skincare. As trailblazers in the early generation of stem cell products, NeoGenesis has become synonymous with the next generation of stem cell science for skin and hair care. At the heart of our success lies our patented S2RM® technology, unlocking the regenerative potential of certified adult stem cell-released molecules. This natural approach to healing, which we proudly term 'systems therapeutics,' is embodied in our products, making a difference in the lives of tens of thousands globally. As we navigate the future, NeoGenesis remains guided by founding principles of innovation, scientific excellence, and a commitment to harnessing the body's inherent healing potential. Join us in shaping the future of skincare through the power of stem cell science.

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.